Expression of Patched-1 Protein in Aggressive and Nonaggressive Basal Cell Carcinoma
American Journal of Clinical and Experimental Medicine
Volume 4, Issue 5, September 2016, Pages: 122-128
Received: Jun. 30, 2016; Accepted: Jul. 30, 2016; Published: Aug. 21, 2016
Views 3419      Downloads 125
Authors
Putu Marcelina, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Alwi Mappiasse, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Anis Irawan Anwar, Department of Dermatology and Venereology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Idham Jaya Ganda, Department of Biostatistic, Faculty of Public Health, Hasanuddin University, Makassar, Indonesia;Department of Pediatrics, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Mohammad Hatta, Department of Microbiology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Rina Masadah, Department of Anatomical Pathology, Medical Faculty, Hasanuddin University, Makassar, Indonesia
Article Tools
Follow on us
Abstract
Basal cell carcinoma (BCC) or basalioma, is a skin cancer characterized by slow-growing, minimal local invasion, rarely metastasize, but can result in extensive morbidity through local invasion and tissue destruction if the treatment was delayed. In this genomic era, aggressiveness of BCC mainly affected by intrinsic factor such as molecular biological dysregulation. The aim of this study was to assess the correlation between level of PTCH1 protein expression and aggressiveness of BCC histopathology. This study was an observational and cross-sectional study with analytical approach, conducted at Outpatient Clinic of Dermatology and Venereology Department of Dr. Wahidin Sudirohusodo Hospital Makassar, Hasanuddin University Hospital, Anatomical Pathology Laboratory of Dr. Wahidin Sudirohusodo and Hasanuddin University Hospital, and Sentra Diagnostic Patologia Laboratory, Makassar from September 2014 to January 2016. Total sample was 37 paraffin block evaluated and classified as aggressive and nonaggressive BCC by histopathological finding. Aggressive type BCCs were 34 samples (91.9%) and nonaggressive type were 3 samples (8.1%). Micronodular type was the most common histopathologic feature in 30 of 37 subjects (81.1%) and 30 of 88 histopathological finding (34.1%). Each subject can have more than one histopathologic type. Percentage of strong expression PTCH1 was found highest in pigmented type (33.4%), the percentage of moderate expression PTCH1 was found highest in infiltrating type (60.0%), and the percentage of negative/weak PTCH1 expression was found highest in the nodular type (75.0%). In this study, the correlation between the aggressiveness and PTCH 1 expression was not significant statistically (p>0.05), but it is seen that the frequency of strong PTCH1 expression was found to be higher in aggressive than nonaggressive BCC.
Keywords
Basal Cell Carcinoma, Patched-1, Aggressive, Nonaggressive
To cite this article
Putu Marcelina, Alwi Mappiasse, Anis Irawan Anwar, Idham Jaya Ganda, Mohammad Hatta, Rina Masadah, Expression of Patched-1 Protein in Aggressive and Nonaggressive Basal Cell Carcinoma, American Journal of Clinical and Experimental Medicine. Vol. 4, No. 5, 2016, pp. 122-128. doi: 10.11648/j.ajcem.20160405.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Walling, H. W., et al., Aggressive basal cell carcinoma: Presentation, pathogenesis, and management. Cancer Metastasis Rev, 2004. 23: p. 389-402.
[2]
Sordo, R. D., A. Cavaliere, and A. Sidoni, Basal Cell Carcinoma With Matrical Differentiation: Expression of.-catenin and Osteopontin. Am J Dermatopathol, 2007. 29: p. 470-4.
[3]
Rubin, A. I., E. H. Chen, and D. Ratner, Current Concepts Basal-Cell Carcinoma. NEJM, 2005. 353: p. 2262-9.
[4]
Leon, A., et al., Assessment of the aggressive feature of basal cell carcinoma in the oral and maxillofacial region. OHDMBSC, 2006. 5 (4): p. 62-67.
[5]
Tilli, C. M. L. J., et al., Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol, 2005. 152: p. 1108-24.
[6]
Goppner, D. and M. Leverkus, Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease. J Skin Cancer, 2011. 2011: p. 650258.
[7]
Zwaan, S. E. d. and N. K. Haass, Genetics of basal cell carcinoma. Australas J Dermatol, 2010. 51: p. 81-94.
[8]
Yahya, Y. F., et al., Profil Karsinoma Sel Basal Primer di RSUP M. Hoesin Palembang. MDVI, 2011. 38 (2): p. 78-83.
[9]
Marcelina, P., et al., Profil Karsinoma Sel Basal di Unit Rawat Jalan Ilmu Kesehatan Kulit dan Kelamin RSUP Dr. Wahidin Sudirohusodo Makassar Tahun 2010-2014, 2014, Departemen Ilmu Kesehatan Kulit dan Kelamin Fakultas Kedokteran Universitas Hasanuddin: Makassar. p. 1-20.
[10]
Tang, J. Y., P.-L. So, and E. H. Epstein, Novel Hedgehog pathway targets against Basal Cell Carcinoma. Toxicol Appl Pharmacol, 2007. 224 (3): p. 257-64.
[11]
Crowson, A. N., Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol, 2006. 19: p. S127-S147.
[12]
Mizuno, T., et al., Molecular basis of basal cell carcinogenesis in the atomic-bomb survivor population: p53 and PTCH gene alterations. Carcinogenesis, 2006. 27 (11): p. 2286-94.
[13]
Fernandes, H., et al., Molecular signatures linked with aggressive behavior in basal cell carcinoma: a report of 6 cases. Am J Dermatopathol, 2010. 32 (6): p. 550-6.
[14]
Lesiak, A., et al., Sonic hedgehog pathway dysregulation in skin basal-cell carcinoma of a Polish population. Folia Histochemica et Cytobiologica, 2013. 51 (3): p. 219-24.
[15]
Tojo, M., et al., Expression of sonic hedgehog signal transducers, patched and smoothened, in human basal cell carcinoma. Pathol Int, 1999. 49: p. 687-94.
[16]
Iwasaki, J. K., et al., The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol, 2012. 66: p. e167-78.
[17]
Marcil, I. and R. S. Stern, Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000. 136: p. 1524-30.
[18]
Raasch, B., P. Buettner, and C. Garbe, Basal cell carcinoma histological classification and body-site distribution. Br J Dermatol, 2006. 155: p. 401-7.
[19]
Chinem, V. P. and H. A. Miot, Epidemiology of basal cell carcinoma. An Bras Dermatol, 2011. 86 (2): p. 292-305.
[20]
Lesiak, A., et al., Risk factors in Central Poland for the development of superficial and nodular basal cell carcinomas. Arch Med Sci, 2010. 6: p. 270-5.
[21]
Abbas, O. L. and H. Borman, Basal Cell Carcinoma: A Single-Center Experience. ISRN Dermatology, 2012. 2012: p. 1-6.
[22]
Gailani, M. R. and A. E. Bale, Developmental Genes and Cancer: Role of Patched in Basal Cell Carcinoma of the Skin. J Natl Cancer Inst 1997. 89: p. 1103-9.
[23]
Stone, D. M., et al., The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature, 1996. 384: p. 129-34.
[24]
Agren, M., et al., Expression of the PTCH1 tumor suppressor gene is regulated by alternative promoters and a single functional Gli-binding site. Gene, 2004. 330: p. 101-14.
[25]
Azterbaum, M., et al., Identification of mutations in human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol, 1998. 110: p. 885-8.
[26]
Škodrić-Trifunović, V., et al., Novel Patched 1 mutations in patients with nevoid basal cell carcinoma syndrome – case report. Croat Med J, 2015. 56: p. 63-7.
[27]
Hendrix, J. J. and H. L. Parlette, Duplicitous growth of infiltrative basal cell carcinoma: Analysis of clinically undetected tumor extent in a paired case control study. Dermatol Surg, 1996. 22: p. 535-9.
[28]
Horlock, N., et al., Cellular proliferation characteristics do not account for the behavior of horrifying basal cell carcinoma. A comparison of the growth fraction of horrifying and nonhorrifying tumors. Brit J Plast Surg, 1998. 51: p. 59-66.
[29]
Kaur, P., M. Mulvaney, and J. A. Carlson, Basal cell carcinoma progression correlates with host immune response and stromal alternations; a histologic analysis. Am J Dermatopathol, 2006. 28 (4): p. 293-306.
[30]
Bertheima, U., et al., The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy. Br Plastic Surgeons, 2004. 57: p. 429-39.
[31]
Haskell, H. D., et al., Basal cell carcinoma with matrical differentiation: a case study with analysis of betacatenin. J Cutan Pathol, 2005. 32 (5): p. 245-50.
[32]
Adegboyega, P. A., S. Rodriguez, and S. J. McLarty, Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. Human Pathology, 2010. 41: p. 1128-37.
[33]
Yahya, Y. F., et al., Ekspresi β catenin dan β4 integrin pada karsinoma sel basal agresif dan non agresif, in Disertasi Program Pascasarjana, Universitas Airlangga, Surabaya, Indonesia. 2010.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186